转移性去势抵抗性前列腺癌患者中甲状腺第二原发恶性肿瘤的偶然检出:68Ga-PSMA-11与64CuCl2 PET/CT记录
本文报告2例转移性去势抵抗性前列腺癌(mCRPC)患者在接受放射性配体治疗前评估时,68Ga-前列腺特异性膜抗原PET/CT偶然检出甲状腺癌,随后多示踪剂PET/CT(64CuCl2和18F-FDG)也观察到该发现。文章据此说明PET/CT在mCRPC背景下具有早期在体检测第二原发肿瘤的潜力。
要点
- 2例mCRPC患者在放射性配体治疗前评估中经68Ga-PSMA PET/CT偶然检出甲状腺癌。
- 随后多示踪剂PET/CT(64CuCl2和18F-FDG)也观察到甲状腺癌。
- 文章说明PET/CT在mCRPC背景下具有早期在体检测第二原发肿瘤的潜力。
核心结论
- 在2例mCRPC患者中,68Ga-PSMA PET/CT偶然检出甲状腺癌,随后多示踪剂PET/CT(64CuCl2和18F-FDG)也观察到该发现,说明PET/CT在mCRPC背景下具有早期在体检测第二原发肿瘤的潜力。
研究设计与样本
- 本文为病例报告,描述2例接受放射性配体治疗前评估的mCRPC患者。
主要发现
- 2例mCRPC患者在放射性配体治疗前评估中,68Ga-PSMA PET/CT初始偶然检出甲状腺癌。
- 上述2例患者的甲状腺癌随后在多示踪剂PET/CT(64CuCl2和18F-FDG)上也被观察到。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Second primary tumors are being increasingly detected owing to and in proportion to the use of advanced imaging modalities including PET/CT. Patients suffering from prostate cancer have been reported to have increased second primary cancers of gastrointestinal tract, urinary bladder, and thyroid. We herein describe incidental detection of thyroid carcinoma, in 2 patients of mCRPC (metastatic castration-resistant prostate carcinoma) undergoing preradioligand therapy workup, on 68 Ga-prostate-specific membrane antigen PET/CT initially, subsequently also observed on multitracer PET/CT ( 64 CuCl 2 and 18 F-FDG). Thus, the potential of PET/CT for early in vivo second primary detection in mCRPC setting is illustrated in the aforementioned 2 patients.
引用
- Nazar A, Kalshetty A, Basu S, et al. Incidental Detection of Second Primary Thyroid Malignancy in Patients of Metastatic Castration-Resistant Prostate Carcinoma: Documentation on 68 Ga-PSMA-11 and 64 CuCl 2 PET/CT. Clin Nucl Med. 2024. PMID: 38768182. doi:10.1097/RLU.0000000000005287
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。